Shots:The UK’s MHRA has approved Oczyesa (octreotide SC depot) for the maintenance treatment in adult with acromegaly who have responded to & tolerated somatostatin analogs, following EC approval on Jun 30, 2025; UK launch expected in Q4’25Approval was based on extensive data from 7 trials, incl. 4 P-I trials, 1 P-II trials &…

Camurus Reports Topline P-IIb (POSITANO) Trial Data on CAM2029 for Symptomatic Polycystic Liver Disease

Shots:Camurus has reported topline P-IIb (POSITANO) trial data assessing 2 dosing regimens of CAM2029 (octreotide SC depot) vs PBO in 71 pts with symptomatic polycystic liver disease (PLD), with pts continuing treatment in a 2.5yr. OLE studyTrial met its 1EP with a 4.3% relative reduction in height-adjusted liver volume at Wk. 53 for…

ByRidhi RastogiJune 18, 2025

NEWS

Eli Lilly Licenses Camurus’ FluidCrystal Technology to Advance Long-Acting Incretin Products

Shots:Camurus has granted Eli Lilly exclusive global rights to research, develop, manufacture, & commercialize long-acting incretin drugs using Camurus’ FluidCrystal tech for cardiometabolic diseases As per the deal, Camurus will receive ~$290M in upfront, development & regulatory milestones as well as $580M in sales-based milestones & global net sales-based tiered royalties in mid-single digits…

ByRidhi RastogiJune 5, 2025

Camurus Receives the MHRA’s Approval for Oczyesa as Maintenance Treatment of Acromegaly

Camurus Reports Topline P-IIb (POSITANO) Trial Data on CAM2029 for Symptomatic Polycystic Liver Disease

Eli Lilly Licenses Camurus’ FluidCrystal Technology to Advance Long-Acting Incretin Products

Contact US

OUR INFORMATION

FOLLOW US